Aceso Plasma, LLC

Beaufort LLC, located in Virginia Beach, VA, specializes in advancing research and product development through a comprehensive range of services, including clinical trial management, biostatistics, and regulatory quality assurance. The company is dedicated to supporting innovations in in vitro diagnostics and medical devices, ensuring compliance and excellence in therapeutic areas, including COVID-19. With a client-first approach, Beaufort emphasizes collaboration and quality across its operations, leveraging expertise in companion diagnostics and regulatory affairs to navigate the complexities of the healthcare landscape. The firm's commitment to high standards is reflected in its ISO 9001:2015 certification and a focus on international and domestic clinical monitoring and oversight. Generated from the website

Light Switch Bio, LLC is a Virginia Beach-based company focused on innovative solutions in the field of photoactivated chemotherapy. They are dedicated to addressing challenges and exploring collaborative opportunities within their area of expertise. The company encourages communication and welcomes inquiries regarding their services or potential partnerships. Light Switch Bio aims to engage with individuals and organizations interested in advancing their work in biotechnology. Generated from the website

ReAlta Life Sciences, Inc., based in Norfolk, VA, is a clinical stage biotechnology company dedicated to addressing rare diseases through innovative therapeutic approaches. The company has developed a novel class of drugs leveraging their EPICC platform, which targets both the complement system and innate inflammatory processes to enhance patient outcomes. Focused on conditions such as Hypoxic Ischemic Encephalopathy, Acute Exacerbations of COPD, Graft-versus-Host Disease, and Platelet Refractoriness, ReAlta Life Sciences aims to modify disease progression by rebalancing inflammatory responses. With a commitment to integrity and patient-centered solutions, the company is actively advancing its clinical pipeline and expanding its research and development initiatives. Generated from the website